Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Gene Therapy for Achromatopsia (CNGA3) (CNGA3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03758404
Recruitment Status : Recruiting
First Posted : November 29, 2018
Last Update Posted : July 29, 2019
Sponsor:
Information provided by (Responsible Party):
MeiraGTx UK II Ltd

Brief Summary:
A clinical trial of AAV - CNGA3 retinal gene therapy for patients with achromatopsia

Condition or disease Intervention/treatment Phase
Achromatopsia Biological: AAV- CNGA3 Phase 1 Phase 2

Detailed Description:
CNGA3 retinal gene therapy for patients with achromatopsia

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/8-hG1.7p.coCNGA3) for Gene Therapy of Children With Achromatopsia Owing to Defects in CNGA3
Actual Study Start Date : July 18, 2019
Estimated Primary Completion Date : May 2021
Estimated Study Completion Date : January 2022


Arm Intervention/treatment
Experimental: Low dose AAV - CNGA3
Subretinal administration of a single low dose of range AAV - CNGA3
Biological: AAV- CNGA3
AAV gene therapy for defects in CNGA3 gene

Experimental: Intermediate dose AAV - CNGA3
Subretinal administration of a single intermediate dose of range AAV - CNGA3
Biological: AAV- CNGA3
AAV gene therapy for defects in CNGA3 gene

Experimental: High dose AAV - CNGA3
Subretinal administration of a single high dose of range AAV - CNGA3
Biological: AAV- CNGA3
AAV gene therapy for defects in CNGA3 gene




Primary Outcome Measures :
  1. Incidence of Adverse Events related to the treatment [ Time Frame: 6 Months ]
    Safety is defined as the absence of ATIMP-related safety events


Secondary Outcome Measures :
  1. Improvement in visual function [ Time Frame: 6 Months ]
    Improvements in visual function as assessed by visual acuity

  2. Improvement in retinal function [ Time Frame: 6 Months ]
    Improvements in retinal function as assessed by microperimetry and perimetry

  3. Improvement in Quality of life [ Time Frame: 6 Months ]
    Quality of life will be measured by QoL questionnaires



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   3 Years to 15 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Are aged 3 to 15 years
  • Have achromatopsia confirmed by a retinal specialist (CI or PI)

Exclusion Criteria:

  • Are females who are pregnant or breastfeeding
  • Have participated in another research study involving an investigational medicinal therapy for ocular disease within the last 6 months
  • Have any other condition that the CI/PI considers makes them inappropriate for entry into the trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03758404


Contacts
Layout table for location contacts
Contact: MeiraGTx UK II Ltd +44 (0)02 3866 4320 ocularinfo@meiragtx.com

Locations
Layout table for location information
United States, Michigan
Kellogg Eye Center Not yet recruiting
Ann Arbor, Michigan, United States, 48105
Contact: Adrienne Chen    734-232-9167    KelloggResearch@med.umich.edu   
Principal Investigator: Cagri Besirli         
United Kingdom
Moorfields Eye Hospital NHS Foundation Trust Recruiting
London, United Kingdom, EC1V 2PD
Contact: James Bainbridge       j.bainbridge@ucl.ac.uk   
Contact: Michel Michaelides       michel.michaelides@ucl.ac.uk   
Principal Investigator: James Bainbridge, Prof         
Sub-Investigator: Michel Michaelides, Prof         
Sponsors and Collaborators
MeiraGTx UK II Ltd
Investigators
Layout table for investigator information
Principal Investigator: James Bainbridge Chief Investigator

Layout table for additonal information
Responsible Party: MeiraGTx UK II Ltd
ClinicalTrials.gov Identifier: NCT03758404     History of Changes
Other Study ID Numbers: MGT012
First Posted: November 29, 2018    Key Record Dates
Last Update Posted: July 29, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Color Vision Defects
Vision Disorders
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Cone Dystrophy
Eye Diseases, Hereditary
Eye Diseases
Signs and Symptoms